Skip to main content
Top
Published in:

Open Access 01-12-2025 | Postpartum Depression | Research

Postpartum depression in relation to chronic diseases and multimorbidity in women’s mid-late life: a prospective cohort study of UK Biobank

Authors: Yue Zhang, Yangyang Cheng, Rodrigo M. Carrillo-Larco, Yaguan Zhou, Hui Wang, Xiaolin Xu

Published in: BMC Medicine | Issue 1/2025

Login to get access

Abstract

Background

Maternal short-term outcomes of postpartum depression (PPD) were widely examined, but little is known about its long-term association with multiple chronic diseases (multimorbidity) in women’s later life. This study aims to assess the association of PPD with chronic diseases and multimorbidity in women’s mid-late life.

Methods

This prospective cohort study included female participants in UK Biobank who attended online follow-up assessment and reported their history of PPD. A total of 36 chronic diseases were assessed and multimorbidity was defined as the co-existence of two or more of these diseases. Participants were followed from the baseline recruitment to the onset of two or more chronic diseases, death, or the end of follow-up (2023). Logistic regression models, Cox proportional hazard models, quasi-Poisson mixed effects models, and linear mixed models were conducted to examine the association of PPD with chronic diseases and multimorbidity at baseline and during follow-up.

Results

Among all 54,885 participants, 5106 (9.3%) participants experienced PPD, 13,928 (25.4%) participants had multimorbidity at baseline, and 14,135 (25.8%) participants developed two or more diseases during a median follow-up of 15 years. Women with a PPD history had higher odds of having multimorbidity at baseline (odds ratio = 1.35, 95% confidence interval [CI] = 1.27–1.44) and higher risk of developing multimorbidity during follow-up (hazard ratio = 1.13, 95% CI = 1.08–1.20). PPD was associated with increased number of chronic diseases, with the relatively new-onset number of diseases during follow-up being 8% higher for those with PPD (relative risk = 1.08, 95% CI = 1.05–1.12). Chronic diseases also accumulated at a faster annual rate for women with a history of PPD (b = 0.009, 95% CI = 0.007–0.011), compared to those without. We observed no interaction or mediation effects of physical activity, smoking, alcohol drinking, and dietary factors on the association between PPD and multimorbidity; however, women’s body mass index at baseline contributed to the association, with the mediation proportion of 6.38% (2.56–10.20%).

Conclusions

PPD was associated with higher risks of chronic diseases and multimorbidity in women’s mid-late life. This finding supports the importance of perinatal and postpartum mental health care, and its role in the prevention of chronic diseases and multimorbidity throughout women’s life course.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Postpartum depression in relation to chronic diseases and multimorbidity in women’s mid-late life: a prospective cohort study of UK Biobank
Authors
Yue Zhang
Yangyang Cheng
Rodrigo M. Carrillo-Larco
Yaguan Zhou
Hui Wang
Xiaolin Xu
Publication date
01-12-2025
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2025
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-025-03853-1

Keynote webinar | Spotlight on innovations in retinal disease

  • Webinar | 08-07-2025 | 18:00 (CEST)

On-demand video coming soon

Retinal diseases are a significant cause of vision impairment and blindness worldwide, but the diagnostic and treatment landscape is rapidly evolving. Explore groundbreaking advances in retinal imaging and gene therapy, before taking a deep dive into emerging treatments for wet AMD.

Prof. Giuseppe Querques
Prof. Dr.med. Katarina Stingl
Dr. Miklos Schneider
Developed by: Springer Medicine
Notify me
Webinar

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest